Previous 10 | Next 10 |
Zentalis Pharmaceuticals (NASDAQ:ZNTL) is collaborating with Caris Life Sciences to support clinical studies for its cancer drug programs. Under the partnership, Caris will sequence individuals’ exome and transcriptome, use real-world data to help inform clinical development and help i...
NEW YORK and SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a stra...
NEW YORK and SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that t...
Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...
NEW YORK and SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that A...
NEW YORK and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that f...
Zentalis Pharmaceuticals press release (NASDAQ:ZNTL): Q4 GAAP EPS of -$1.11 beats by $0.22. As of December 31, 2021, cash, cash equivalents and marketable securities of $339.9M For further details see: Zentalis Pharmaceuticals GAAP EPS of -$1.11 beats by $0.22
Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor, ZN-c3, for the treatment of uterine serous carcinoma (USC) Initiated two additional trials with ZN-c3, including a potentially registrational biomarker-driven Phase 2 trial and a Pha...
Halvorsen's 13F portfolio value increased from $32.98B to $36.04B this quarter. The number of positions increased from 88 to 96. Viking Global added McDonald’s and increased General Electric, Humana, Brookfield Asset Management, and Parker Hannifin while dropping Aon plc during...
NEW YORK and SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is hosting a virtual R&...
News, Short Squeeze, Breakout and More Instantly...
Zentalis Pharmaceuticals Inc. Company Name:
ZNTL Stock Symbol:
NASDAQ Market:
Zentalis Pharmaceuticals Inc. Website:
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is one of today's top gainers. The company's shares have moved 30.16% on the day to $5.39. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatme...
2024-06-20 08:30:04 ET UBS analyst issues NEUTRAL recommendation for ZNTL on June 20, 2024 06:35AM ET. ZNTL was trading at $4.14 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 4 - Hold recommend...
A look at the top 10 most actives in the United States Reliance Global Group Inc. (RELI) rose 76.2% to $0.3911 on volume of 383,719,808 shares NLS Pharmaceutics Ltd. (NLSP) rose 82.1% to $0.2701 on volume of 302,290,803 shares NVIDIA Corporation (NVDA) rose 3.5% to $135.58 on volume of 28...